Abstract
In the general classification of cancer prevention, chemoprevention is defined as an intervention to prevent carcinogenesis by the reverse or the arrest of transformed clones using a physiological mechanism. The reverse of such clones is done by differentiation induction, and the arrest is mainly achieved by apoptosis induction. The concept of chemoprevention, thus, requires that the target organ essentially contains premalignant or latent malignant clones. In this assumption, premalignant clones respond to the transformed cells on the promotion or conversion phase of multistep carcinogenesis, and latent malignant clones indicate the cells on the progression phase. The latter clone is regarded to have already completed the genomic and molecular process of carcinogenesis, but can not yet be detected using common diagnostic modalities such as medical imagings and serum tumor markers. Successful chemoprevention is performed by deletion of these clones and, thus, is also called clonal deletion. In the case of liver cancer, those transformed clones are supposed to exist in cirrhotic liver including remnant liver after surgical resection or ablation therapy of initial HCC.
Recent advances in the studies on cancer chemoprevention revealed that the most promising molecular target is nuclear steroid hormone receptor super-family proteins. These receptors include ER, TR, RAR, RXR, PPAR, VDR and others, and regulate cellular differentiation and programmed cell death as ligand-dependent transcription factors. In hepatitis virus-related liver carcinogenesis, the role of RXR and RAR seems to be important from recent experimental analyses. In particular, malfunction of RXR is the most recent topic in the mechanism of liver carcinogenesis (Cancer Res 2001, Hepatology 2002).
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Hong WK, Sporn MB. Recent advances in chemoprevention of cancer. Science 1997;278:1073–1077.
Moriwaki H. Prevention of liver cancer: basic and clinical aspects. Exp Mol Med 2002;34:319–325.
Sporn MB, Newton DL. Chemoprevention of cancer with retinoids. Fed Proc 1979;38:2528–2534.
Altucci L, Gronemeyer H. The promise of retinoids to fight against cancer. Nat Rev Cancer 2001;1:181–193.
Muto Y, Moriwaki H, Ninomiya M, Adachi S, Saito A, Takasaki KT, Tanaka T, Tsurumi K, Okuno M, Tomita E, Nakamura T, Kojima T. Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. N Engl J Med 1996;334:1561–1567.
Muto Y, Moriwaki H, Saito A. Prevention of second primary tumors by an acyclic retinoid in patients with hepatocellular carcinoma. N Engl J Med 1999;340:1046–1047.
Moriwaki H, Yasuda I, Shiratori Y, Uematsu T, Okuno M, Muto Y. Deletion of serum lectin-reactive alpha-fetoprotein by acyclic retinoid: a potent biomarker in the chemoprevention of second primary hepatoma. Clin Cancer Res 1997;3:727–731.
Yasuda I, Shiratori Y, Adachi S, Obora A, Takemura M, Okuno M, Shidoji Y, Seishima M, Muto Y, Moriwaki H. Acyclic retinoid induces partial differentiation, down-regulates telomerase reverse transcriptase mRNA expression and telomerase activity, and induces apoptosis in human hepatoma-derived cell lines. J Hepatol 2002;36:660–671.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2004 Springer Japan
About this paper
Cite this paper
Moriwaki, H. (2004). Chemoprevention of Hepatocellular Carcinoma with Retinoid. In: Omata, M., Okita, K. (eds) Therapy for Viral Hepatitis and Prevention of Hepatocellular Carcinoma. Springer, Tokyo. https://doi.org/10.1007/978-4-431-53977-3_23
Download citation
DOI: https://doi.org/10.1007/978-4-431-53977-3_23
Publisher Name: Springer, Tokyo
Print ISBN: 978-4-431-67975-2
Online ISBN: 978-4-431-53977-3
eBook Packages: Springer Book Archive